{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T10:50:18Z","timestamp":1772016618301,"version":"3.50.1"},"reference-count":48,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"FEDER\u2014Fundo Europeu de Desenvolimento Regional","award":["F\/00092\/2014\/CP1255\/CT0004"],"award-info":[{"award-number":["F\/00092\/2014\/CP1255\/CT0004"]}]},{"name":"FCT\u2014Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","award":["F\/00092\/2014\/CP1255\/CT0004"],"award-info":[{"award-number":["F\/00092\/2014\/CP1255\/CT0004"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Entecavir (ETV) is a drug used as a first-line treatment for chronic hepatitis B (CHB) virus infection because it is a guanosine nucleoside analogue with activity against the hepatitis B virus polymerase. The ETV dosage can range from 0.5 mg to 1 mg once a day and the most common side effects include headache, insomnia, fatigue, dizziness, somnolence, vomiting, diarrhea, nausea, dyspepsia, and increased liver enzyme levels. In addition to its conventional use, ETV acts as an inhibitor of lysine-specific demethylase 5B (KDM5B), an enzyme that is overexpressed in breast, lung, skin, liver, and prostate tumors and is involved in the hormonal response, stem cell regeneration, genomic stability, cell proliferation, and differentiation. The KDM5B enzyme acts as a transcriptional repressor in tumor suppressor genes, silencing them, and its overexpression leads to drug resistance in certain tumor types. Furthermore, the literature suggests that KDM5B activates the PI3K\/AKT signaling pathway, while reducing KDM5B expression decreases AKT signaling, resulting in decreased tumor cell proliferation. In silico studies have demonstrated that ETV can inhibit tumor cell proliferation and induce apoptosis by reducing KDM5B expression. ETV also appears to inhibit PARP-1, has a high genetic barrier, reducing the chance of resistance development, and can also prevent the reactivation of the hepatitis B virus in cancer patients, which have proven to be significant advantages regarding its use as a repurposed drug in oncology. Therefore, ETV holds promise beyond its original therapeutic indication.<\/jats:p>","DOI":"10.3390\/ph16111603","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T02:20:37Z","timestamp":1699928437000},"page":"1603","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Entecavir: A Review and Considerations for Its Application in Oncology"],"prefix":"10.3390","volume":"16","author":[{"given":"T\u00e2nia","family":"Louren\u00e7o","sequence":"first","affiliation":[{"name":"PerMed Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"},{"name":"CINTESIS@RISE, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1283-1042","authenticated-orcid":false,"given":"Nuno","family":"Vale","sequence":"additional","affiliation":[{"name":"PerMed Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"},{"name":"CINTESIS@RISE, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"Department of Community Medicine, Information and Health Decision Sciences (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,14]]},"reference":[{"key":"ref_1","unstructured":"Hepatitis, B. (2023, August 07). Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Shang, J., Zhou, J., Liu, H., Ise, R.M., Tu, Y., Ran, J., Bai, L., and Tang, H. (2021). Efficacy of Different Nucleoside Analog Rescue Therapies for Entecavir-Resistant Chronic Hepatitis B Patients. BMC Infect. Dis., 21.","DOI":"10.1186\/s12879-021-06554-1"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Prifti, G.M., Moianos, D., Zoidis, G., Giannakopoulou, E., Pardali, V., Tavis, J.E., and Grigoris, Z. (2021). Recent Advances in Hepatitis b Treatment. Pharmaceuticals, 14.","DOI":"10.3390\/ph14050417"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3350\/cmh.2016.0040","article-title":"Efficacy and Safety of Entecavir versus Lamivudine over 5 Years of Treatment: A Randomized Controlled Trial in Korean Patients with Hepatitis B e Antigen-Negative Chronic Hepatitis B","volume":"23","author":"Lee","year":"2017","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_5","first-page":"51","article-title":"The Discovery and Development of a Potent Antiviral Drug, Entecavir, for the Treatment of Chronic Hepatitis B","volume":"1","author":"Tang","year":"2013","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_6","unstructured":"(2023, September 20). Baraclude. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/baraclude-epar-product-information_pt.pdf."},{"key":"ref_7","unstructured":"(2023, May 20). Entecavir, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Entecavir."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.2147\/DDDT.S149199","article-title":"Baracle\u00ae vs. Baraclude\u00ae for 48 Weeks in Patients with Treatment-Na\u00efve Chronic Hepatitis B: A Comparison of Efficacy and Safety","volume":"11","author":"Kim","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"189","DOI":"10.5009\/gnl15562","article-title":"Management of Antiviral Resistance in Chronic Hepatitis B","volume":"11","author":"Lim","year":"2017","journal-title":"Gut Liver"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S174","DOI":"10.1002\/hep.22900","article-title":"Antiviral Resistance and Hepatitis B Therapy","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3259833","DOI":"10.1155\/2021\/3259833","article-title":"Clinical Features and Resistance to Entecavir Monotherapy of Patients with Hepatitis B","volume":"2021","author":"Takayama","year":"2021","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"16251","DOI":"10.1038\/s41598-021-95507-4","article-title":"Exploring the Selectivity of Guanine Scaffold in Anticancer Drug Development by Computational Repurposing Approach","volume":"11","author":"Sherin","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.20344\/amp.13870","article-title":"PARP Inhibitors: From the Mechanism of Action to Clinical Practice","volume":"35","author":"Branco","year":"2022","journal-title":"Acta Med. Port."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Congregado, B., Rivero, I., Osm\u00e1n, I., S\u00e1ez, C., and L\u00f3pez, R.M. (2022). PARP Inhibitors: A New Horizon for Patients with Prostate Cancer. Biomedicines, 10.","DOI":"10.3390\/biomedicines10061416"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2147\/IJN.S290438","article-title":"Application of Radiosensitizers in Cancer Radiotherapy","volume":"16","author":"Gong","year":"2021","journal-title":"Int. J. Nanomed."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"25549","DOI":"10.18632\/oncotarget.8224","article-title":"Phase I Trial Evaluating the Antiviral Agent Cidofovir in Combination with Chemoradiation in Cervical Cancer Patients","volume":"7","author":"Deutsch","year":"2016","journal-title":"Oncotarget"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Pereira, M., and Vale, N. (2022). Repurposing Alone and in Combination of the Antiviral Saquinavir with 5-Fluorouracil in Prostate and Lung Cancer Cells. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232012240"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.cld.2020.04.002","article-title":"Hepatitis B Virus Reactivation: What Is the Issue, and How Should It Be Managed?","volume":"24","author":"Ekpanyapong","year":"2020","journal-title":"Clin. Liver Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5769","DOI":"10.12998\/wjcc.v9.i21.5769","article-title":"Prevention of Hepatitis B Reactivation in Patients Requiring Chemotherapy and Immunosuppressive Therapy","volume":"9","author":"Shih","year":"2021","journal-title":"World J. Clin. Cases"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/s40425-019-0808-5","article-title":"Hepatitis B Virus Reactivation in Cancer Patients with Positive Hepatitis B Surface Antigen Undergoing PD-1 Inhibition","volume":"7","author":"Zhang","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Jose, A., Shenoy, G.G., Rodrigues, G.S., Kumar, N.A.N., Munisamy, M., Thomas, L., Kolesar, J., Rai, G., Rao, P.P.N., and Rao, M. (2020). Histone Demethylase KDM5B as a Therapeutic Target for Cancer Therapy. Cancers, 12.","DOI":"10.3390\/cancers12082121"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Ohguchi, Y., and Ohguchi, H. (2022). Diverse Functions of KDM5 in Cancer: Transcriptional Repressor or Activator?. Cancers, 14.","DOI":"10.3390\/cancers14133270"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1158\/0008-5472.CAN-20-0505","article-title":"KDM5B Is Essential for the Hyper-Activation of PI3K\/AKT Signaling in Prostate Tumorigenesis","volume":"80","author":"Li","year":"2020","journal-title":"Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1038\/s12276-022-00902-0","article-title":"Drawing a Line between Histone Demethylase KDM5A and KDM5B: Their Roles in Development and Tumorigenesis","volume":"54","author":"Yoo","year":"2022","journal-title":"Exp. Mol. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/s41417-022-00584-w","article-title":"A Truncated and Catalytically Inactive Isoform of KDM5B Histone Demethylase Accumulates in Breast Cancer Cells and Regulates H3K4 Tri-Methylation and Gene Expression","volume":"30","author":"Licursi","year":"2023","journal-title":"Cancer Gene Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13058-019-1228-7","article-title":"Inhibition of the Histone Demethylase, KDM5B, Directly Induces Re-Expression of Tumor Suppressor Protein HEXIM1 in Cancer Cells","volume":"21","author":"Montano","year":"2019","journal-title":"Breast Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.52793\/ACMR.2023.4(3)-58","article-title":"The Role of Tumor Suppressor Gene Epigenetic Regulation in the Prognosis of Chemotherapy Resistance and Aggressiveness of Breast and Lung Cancer","volume":"4","author":"Kaur","year":"2023","journal-title":"Adv. Clin. Med. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"112760","DOI":"10.1016\/j.ejmech.2020.112760","article-title":"Targeting Histone Demethylase KDM5B for Cancer Treatment","volume":"208","author":"Fu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"757497","DOI":"10.3389\/fonc.2021.757497","article-title":"Mechanisms of JARID1B Up-Regulation and Its Role in Helicobacter Pylori-Induced Gastric Carcinogenesis","volume":"11","author":"Zheng","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_30","first-page":"87","article-title":"KDM5B Is Overexpressed in Gastric Cancer and Is Required for Gastric Cancer Cell Proliferation and Metastasis","volume":"5","author":"Wang","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"ref_31","first-page":"2364","article-title":"NEK2 Promotes Proliferation, Migration and Tumor Growth of Gastric Cancer Cells via Regulating KDM5B\/H3K4me3","volume":"9","author":"Li","year":"2019","journal-title":"Am. J. Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/s41467-023-37568-9","article-title":"Expression-Based Subtypes Define Pathologic Response to Neoadjuvant Immune-Checkpoint Inhibitors in Muscle-Invasive Bladder Cancer","volume":"14","author":"Robertson","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13046-016-0311-5","article-title":"Depletion of Histone Demethylase KDM5B Inhibits Cell Proliferation of Hepatocellular Carcinoma by Regulation of Cell Cycle Checkpoint Proteins P15 and P27","volume":"35","author":"Wang","year":"2016","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5949","DOI":"10.1111\/jcmm.16342","article-title":"KDM5B Promotes Self-Renewal of Hepatocellular Carcinoma Cells through the MicroRNA-448\u2013Mediated YTHDF3\/ITGA6 Axis","volume":"25","author":"Guo","year":"2021","journal-title":"J. Cell. Mol. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1002\/hep4.1967","article-title":"Alcohol-Associated Fibrosis in Females Is Mediated by Female-Specific Activation of Lysine Demethylases KDM5B and KDM5C","volume":"6","author":"Schonfeld","year":"2022","journal-title":"Hepatol. Commun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"118726","DOI":"10.1016\/j.lfs.2020.118726","article-title":"Lysine Demethylase 5B Suppresses CC Chemokine Ligand 14 to Promote Progression of Colorectal Cancer through the Wnt\/\u03b2-Catenin Pathway","volume":"264","author":"Yan","year":"2021","journal-title":"Life Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12964-020-00660-4","article-title":"JARID1B Promotes Colorectal Cancer Proliferation and Wnt\/\u03b2-Catenin Signaling via Decreasing CDX2 Level","volume":"18","author":"Huang","year":"2020","journal-title":"Cell Commun. Signal."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Metzler, V.M., de Brot, S., Haigh, D.B., Woodcock, C.L., Lothion-Roy, J., Harris, A.E., Nilsson, E.M., Ntekim, A., Persson, J.L., and Robinson, B.D. (2023). The KDM5B and KDM1A Lysine Demethylases Cooperate in Regulating Androgen Receptor Expression and Signalling in Prostate Cancer. Front. Cell Dev. Biol., 11.","DOI":"10.3389\/fcell.2023.1116424"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3389\/fphys.2018.00500","article-title":"Drug Repositioning for Effective Prostate Cancer Treatment","volume":"9","author":"Turanli","year":"2018","journal-title":"Front. Physiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e002","DOI":"10.4172\/2329-6887.S2-e002","article-title":"Advantages and Challenges in Drug Re-Profiling","volume":"S2","author":"Agrawal","year":"2015","journal-title":"J. Pharmacovigil."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"886","DOI":"10.3332\/ecancer.2018.886","article-title":"ReDO_DB: The Repurposing Drugs in Oncology Database","volume":"12","author":"Pantziarka","year":"2018","journal-title":"Ecancermedicalscience"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.urology.2008.10.005","article-title":"Conventional Treatments of Localized Prostate Cancer","volume":"72","author":"Zerbib","year":"2008","journal-title":"Urology"},{"key":"ref_43","first-page":"228","article-title":"Options for Curative Treatment of Localized Prostate Cancer","volume":"118","author":"Knipper","year":"2021","journal-title":"Dtsch. Arztebl. Int."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.5489\/cuaj.7272","article-title":"Active Surveillance in Favorable Intermediate-Risk Prostate Cancer Patients: Predictors of Deferred Intervention and Treatment Choice","volume":"16","author":"Sayyid","year":"2021","journal-title":"Can. Urol. Assoc. J."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Duarte, D., and Vale, N. (2022). Antidepressant Drug Sertraline against Human Cancer Cells. Biomolecules, 12.","DOI":"10.3390\/biom12101513"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Louren\u00e7o, T., and Vale, N. (2023). Pharmacological Efficacy of Repurposing Drugs in the Treatment of Prostate Cancer. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24044154"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.drudis.2016.05.015","article-title":"Drug Combination Therapy Increases Successful Drug Repositioning","volume":"21","author":"Sun","year":"2016","journal-title":"Drug Discov. Today"},{"key":"ref_48","unstructured":"FDA (2023, September 15). Antiviral Drug Advisory Committee Recommends Unanymously to Approve Entecavir for Hepatitis B. Available online: https:\/\/www.natap.org\/2005\/HBV\/031505_02.htm."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/11\/1603\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:22:32Z","timestamp":1760131352000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/11\/1603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,14]]},"references-count":48,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["ph16111603"],"URL":"https:\/\/doi.org\/10.3390\/ph16111603","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,14]]}}}